Solasia Pharma K.k. (4597.T) Stock

4597.T logo

Solasia Pharma K.k.

4597.TJapan
Healthcare

Company profile

Solasia Pharma K.k. reported revenue of 429.00 million JPY for fiscal year 2025. Our analysis of its filings shows revenue shrinking from 617.00 million JPY in fiscal year 2023 to 429.00 million JPY in fiscal year 2025, 16.6% a year on average. Solasia Pharma K.k. reports about 22 full-time employees.

What stands out

  • It reported a net loss in each of its last 5 fiscal years; the loss narrowed from 1.94 billion JPY in fiscal year 2024 to 876.00 million JPY in fiscal year 2025.
  • Revenue rose 35.8% in fiscal year 2025, from 316.00 million JPY in fiscal year 2024, after a fall of 48.8% the year before.
  • It spent 430.00 million JPY on research and development in fiscal year 2025, more than its revenue.
  • China and Others brought in 69% of revenue by region in fiscal year 2025, up from 59% in fiscal year 2024; the company is based in Japan.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Solasia Pharma K.k.

Solasia Pharma K.K. develops, markets, imports, and exports pharmaceutical products and medical devices in Japan, China, South Korea, and internationally. The company offers Episil (SP-03), an oral liquid for oral mucositis/stomatitis; DARVIAS (SP-02), an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso (SP-01) for chemotherapy-induced nausea and vomiting. It also develops SP-04, which is in a preclinical trial for chemotherapy-induced peripheral neuropathy; and SP-05, which is in a preclinical trial for colorectal cancer. The company was formerly known as JapanBridge, Inc. and changed its name to Solasia Pharma K.K. in September 2008. Solasia Pharma K.K. was founded in 2006 and is headquartered in Minato, Japan.

Largest shareholders

  • Nippon Kayaku Co., Ltd.4.39%
  • Maruho Co., Ltd.4.14%
  • Macquarie Bank Ltd. (Private Banking)3.07%
  • Yoshihiro Arai0.5795 %0.58%
  • Hiroyuki Isogai0.5794 %0.58%

Share of the company, as of May 19, 2026

Leadership

  • Yoshihiro Arai — President, CEO & Representative Director, 65
  • Toshio Miyashita — CFO, Head of Administration & Director, 58
  • Yasumitsu Shimada — Accounting Manager
  • Yasuaki Manabe — Head of Marketing Division
  • Fumiko Nagahama — Head of Product Development Division

How much revenue does Solasia Pharma K.k. make?

Solasia Pharma K.k. reported 429.00 million JPY in revenue for fiscal year 2025, up 35.8% from 316.00 million JPY in fiscal year 2024.

Where does Solasia Pharma K.k. make most of its revenue?

China and Others: 69% of revenue by region in fiscal year 2025, followed by Japan (31%).

What companies are similar to Solasia Pharma K.k.?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Aska Pharmaceutical Holdings Co.,Ltd. (4886.T), Fuji Pharma Co., Ltd. (4554.T), StemRIM (4599.T), Nippon Chemiphar Co., Ltd. (4539.T).

Has Solasia Pharma K.k. made a profit in recent years?

Net income by fiscal year: FY2021, a loss of 2.48 billion JPY; FY2022, a loss of 2.55 billion JPY; FY2023, a loss of 1.11 billion JPY; FY2024, a loss of 1.94 billion JPY; FY2025, a loss of 876.00 million JPY. It reported a net loss in each of these 5 years.

How has Solasia Pharma K.k.'s revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 559.00 million JPY; FY2022, 1.09 billion JPY; FY2023, 617.00 million JPY; FY2024, 316.00 million JPY; FY2025, 429.00 million JPY.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees22
FoundedDec 2006
IPO DateMar 24, 2017
IPO StatusPublic
HeadquartersMinato, Japan
FoundersBard Geesaman
ExchangeTokyo
TimezoneAsia/Tokyo (JST)

Contact & Links

Address
Sumitomo Fudosan Shiba-Koen Tower, Minato, 105-0011
Phone
81 3 5843 8046
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Solasia Pharma K.k. (4597.T)”, data as of May 19, 2026, https://dataporium.tech/stocks/4597.T

LinkedInLinkedInXXYouTubeYouTube